CBIO FY 2024 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$345M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$35,174

Operating Income

-$69M

Net Income

-$71M

EPS (Diluted)

$-0.59

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$36M

Total Liabilities

$51M

Stockholders' Equity

$5M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$10,000	-100.0%
Gross Profit	-$35,174	$10,000	-451.7%
Operating Income	-$69M	-$39M	-75.1%
Net Income	-$71M	-$37M	-93.7%